Opendata, web and dolomites

PhagoPROD SIGNED

GMP manufacturing & GLP diagnostic: Towards a personalised phage therapy against antimicrobial resistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PhagoPROD project word cloud

Explore the words cloud of the PhagoPROD project. It provides you a very rough idea of what is the project "PhagoPROD" about.

pathogenic    scaling    selling    2017    sme    suffering    forecast    demonstrated    hopeful    drug    authorisation    notably    clinical    gmp    bacterial    resistant    lasting    antibiotic    human    administrate    1st    hospital    france    centres    transnational    usa    associations    90    reaching    leader    million    ansm    diagnostics    launch    500    ultimate    customers    levels    deaths    2006    attributable    french    bacteriophages    answer    patients    lien    patented    compassionate    status    therapeutic    final    pharma    treatment    frame    portfolio    point    le    pherecydes    company    50    commercial    phages    phagespoirs    bacteria    relationships    world    buyers    manufacturing    ones    building    validated    first    multicentric    designed    pharmacists    curent    created    regard    hospitals    successes    optimising    prescribers    glp    phage    benefits    setting    almost    laboratory    manufacture    therapy    2050    infections    phagoprod    plague   

Project "PhagoPROD" data sheet

The following table provides information about the project.

Coordinator
PHERECYDES PHARMA SA 

Organization address
address: NANTES BIOTECH 22 BOULEVARD BENONI GOULLIN
city: NANTES
postcode: 44200
website: www.pherecydes-pharma.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙764˙172 €
 EC max contribution 2˙446˙712 € (65%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHERECYDES PHARMA SA FR (NANTES) coordinator 2˙446˙712.00

Map

 Project objective

Phage therapy, that is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections, is a highly promising answer to the antibiotic resistant plague (500 000 deaths a year attributable to multi-drug resistant bacteria today, 10 million forecast by 2050). In this hopeful field, Pherecydes Pharma, a French SME created in 2006, is currently the world leader of phage therapy, with a a unique selling point and value proposal: (1) Patented technology; (2) Curent product portfolio covering over 50% of human infections and almost 90% of multi-drug resistant ones; (3) Ability to manufacture phages in GMP conditions; (4) 1st company to launch a transnational, well-designed, well-controlled, multicentric clinical study; (5) French authorisation (ANSM) in 2017 to administrate Pherecydes Pharma bacteriophages under a compassionate use status. Building on these successes, the PhagoPROD project aims at setting-up, optimising and scaling-up the GMP manufacturing and GLP diagnostics processes currently validated and demonstrated at laboratory scale. In that so, the ultimate objective is to achieve large-scale commercial exploitation of Pherecydes Pharma products first at the EU then at the USA levels (world reaching is planned in the long term). In the frame of this future commercial exploitation, targeted final users will be patients suffering from bacterial infections, notably antibiotic-resistant ones. Customers (i.e. buyers of Pherecydes Pharma products) will be clinical prescribers and hospital pharmacists. In this regard, Pherecydes already benefits from strong and long-lasting relationships with many hospitals and clinical centres in France and in Europe, as well as with several patients' associations (e.g. Le Lien or Phagespoirs).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHAGOPROD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PHAGOPROD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

Cortx (2019)

Intelligent debt recovery platform.

Read More